These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20395409)

  • 21. Transglutaminase as a therapeutic target for celiac disease.
    Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
    Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism.
    Palanski BA; Khosla C
    Biochemistry; 2018 Jun; 57(24):3359-3363. PubMed ID: 29570977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Déjà vu with a twist: transglutaminases in bioenergetics and transcriptional dysfunction in Huntington's disease.
    Kazemi-Esfarjani P; La Spada AR
    EMBO Mol Med; 2010 Sep; 2(9):335-7. PubMed ID: 20730854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of tissue transglutaminase.
    Keillor JW; Apperley KY; Akbar A
    Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
    Watts RE; Siegel M; Khosla C
    J Med Chem; 2006 Dec; 49(25):7493-501. PubMed ID: 17149878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis.
    Daneshpour N; Griffin M; Collighan R; Perrie Y
    J Drug Target; 2011 Sep; 19(8):624-31. PubMed ID: 21067461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
    Karpuj MV; Becher MW; Springer JE; Chabas D; Youssef S; Pedotti R; Mitchell D; Steinman L
    Nat Med; 2002 Feb; 8(2):143-9. PubMed ID: 11821898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue transglutaminase inhibition.
    Keillor JW
    Chem Biol; 2005 Apr; 12(4):410-2. PubMed ID: 15850975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement.
    Strnad P; Harada M; Siegel M; Terkeltaub RA; Graham RM; Khosla C; Omary MB
    Gastroenterology; 2007 Apr; 132(4):1515-26. PubMed ID: 17408647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism for the inhibition of transglutaminase 2 by cystamine.
    Jeitner TM; Delikatny EJ; Ahlqvist J; Capper H; Cooper AJ
    Biochem Pharmacol; 2005 Mar; 69(6):961-70. PubMed ID: 15748707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
    Mehta K; Kumar A; Kim HI
    Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
    Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
    Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
    Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
    Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of allosteric regulation of transglutaminase 2 by GTP.
    Begg GE; Carrington L; Stokes PH; Matthews JM; Wouters MA; Husain A; Lorand L; Iismaa SE; Graham RM
    Proc Natl Acad Sci U S A; 2006 Dec; 103(52):19683-8. PubMed ID: 17179049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential of transglutaminase 2 as a therapeutic target.
    Caccamo D; Currò M; Ientile R
    Expert Opin Ther Targets; 2010 Sep; 14(9):989-1003. PubMed ID: 20670177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transglutaminase inhibitors: a patent review.
    Keillor JW; Apperley KY
    Expert Opin Ther Pat; 2016; 26(1):49-63. PubMed ID: 26560530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
    Pardin C; Roy I; Lubell WD; Keillor JW
    Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein.
    Király R; Demény M; Fésüs L
    FEBS J; 2011 Dec; 278(24):4717-39. PubMed ID: 21902809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.